Bronnen:
Viswanathan HN, Lipton RB, Ailani J, et al. Improved Functionality, Pain Relief, and Satisfaction in Patients Treated With Ubrogepant vs Placebo: Results from 2 Single-Attack Phase 3 Studies, ACHIEVE I and II. AAN 2019, P2.10-012.,Ailani J, Hutchinson S, Lipton RB, et al. Long-Term Safety Evaluation of Ubrogepant for the Acute Treatment of Migraine. AAN 2019, P2.10-009.,Jakate A, Boinpally R, Butler M, et al. Single Therapeutic and Supratherapeutic Doses of Ubrogepant Do Not Affect Cardiac Repolarization in Healthy Adults. AAN 2019, P2.10-003.
Viswanathan HN, Lipton RB, Ailani J, et al. Improved Functionality, Pain Relief, and Satisfaction in Patients Treated With Ubrogepant vs Placebo: Results from 2 Single-Attack Phase 3 Studies, ACHIEVE I and II. AAN 2019, P2.10-012.,Ailani J, Hutchinson S, Lipton RB, et al. Long-Term Safety Evaluation of Ubrogepant for the Acute Treatment of Migraine. AAN 2019, P2.10-009.,Jakate A, Boinpally R, Butler M, et al. Single Therapeutic and Supratherapeutic Doses of Ubrogepant Do Not Affect Cardiac Repolarization in Healthy Adults. AAN 2019, P2.10-003.